FindTrial
Sign In

A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500797-34-00
Acronym
MK-7339-002
Enrollment
27
Registered
2023-02-22
Start date
2018-12-17
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of participants with positive cancer for HRRm or HRD.

Brief summary

Objective Response Rate (ORR)

Detailed description

Duration of Response (DOR), Overall Survival (OS), Progression Free Survival (PFS), Number of Participants Experiencing an Adverse Event (AE), Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE), Objective Response Rate (ORR) in Participants with HRRm or HRD Positive Cancer, Time to Earliest Progression by Cancer Antigen-125 (CA-125), Prostate-specific Antigen (PSA) Response Rate in Participants with Prostate Cancer, Progression-Free Survival After Next-Line Treatment in Participants with sBRCAm Breast Cancer

Interventions

DRUGOlaparib

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Objective Response Rate (ORR)—

Secondary

MeasureTime frame
Duration of Response (DOR), Overall Survival (OS), Progression Free Survival (PFS), Number of Participants Experiencing an Adverse Event (AE), Number of Participants Discontinuing Study Treatment due to an Adverse Event (AE), Objective Response Rate (ORR) in Participants with HRRm or HRD Positive Cancer, Time to Earliest Progression by Cancer Antigen-125 (CA-125), Prostate-specific Antigen (PSA) Response Rate in Participants with Prostate Cancer, Progression-Free Survival After Next-Line Treatment in Participants with sBRCAm Breast Cancer—

Countries

Denmark, France, Ireland, Italy, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026